Introduction
Gastric cancer (GC) is considered the third-leading cause of death among all cancer types and has caused 723,000 deaths across the whole world. 1, 2 Currently, the incidence of GC has been significantly increasing, with ~952,000 new cases each year.
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cheng et al rate is ,20% at this stage. 1, 4 Chemotherapy (CT) is one of the standard treatment regimens for advanced GC. Although CT improves patient survival, most patients eventually relapse and develop resistance to treatment, which is not able to completely eradicate small lesions and metastatic cells. 1, [5] [6] [7] Thus, more effective and safer treatments are urgently required.
In recent years, the use of molecular targeted therapy has been increasing rapidly, and this approach is considered as a powerful therapeutic method for cancer treatment. The agents used in targeted therapy can precisely identify and attack certain type of cancer cells based on mutations of genes and proteins. 2 Moreover, little damage is done to normal cells; thus, molecular targeted therapy is also called a "biological missile." The clinical application of molecular targeted therapy for malignancies has been reported, and several studies have found that the combination of molecular targeted therapy and CT has better therapeutic effects than treatment with CT alone. [8] [9] [10] [11] [12] [13] Angiogenesis is essential for tumor growth and metastasis, and VEGF and its receptors (VEGFRs) play a crucial role in angiogenesis. [14] [15] [16] VEGFR2 is one of 3 VEGFRs and plays a pivotal role in VEGF-mediated cancer angiogenesis. 17 Apatinib is a novel antiangiogenic agent that specifically targets VEGFR2. This small molecule tyrosine kinase inhibitor was approved for the second-line treatment of advanced GC in the People's Republic of China in 2014. 17, 18 In several clinical trials, apatinib targeted therapy combined with CT exhibited more prominent therapeutic effects for advanced GC than CT alone. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] However, systematic analyses assessing the therapeutic efficacy of apatinib targeted therapy combined with CT in advanced GC remain scarce. In this study, we conducted a meta-analysis to investigate the treatment effect and safety of apatinib targeted therapy combined with CT in comparison with CT alone for advanced GC to provide a scientific reference for the design of future clinical trials.
Materials and methods search strategy and selection criteria
The literature was searched across PubMed, the Cochrane Library, Web of Science, EMBASE, CNKI, and the Wanfang database with key terms "apatinib" combined with "gastric cancer." No language limits were applied. The initial search was performed in January 2018 and updated in March 2018.
Selection criteria: Studies concerning advanced GC patients were involved in our analysis. Patients in the experimental groups received apatinib targeted therapy combined with CT, and patients in the control group were treated with CT alone.
Data extraction and quality assessment
The data were independently extracted by 2 investigators (Honggang Cheng and Aixia Sun). Disagreements were resolved by discussion with a third researcher (Qingbo Guo). All involved studies were summarized as follows: the first author's name, year of publication, study location, tumor stages, number of cases, patient ages, study parameter types, therapeutic regimens, enrollment period, and dosages of apatinib utilized. The included trials' qualities were evaluated based on the Cochrane Handbook. 38 
Outcome definition
The clinical responses included treatment efficacy, quality of life (QOL), and adverse events (AEs). Treatment efficacy was assessed in terms of the complete response rate (CR), partial response rate (PR), stable disease rate (SD), progressive disease rate (PD), overall response rate (ORR, ORR=CR+PR), and disease control rate (DCR, DCR=CR+PR+SD). The patients' QOLs were evaluated using the QOL improved rate (QIR) and the Karnofsky performance score (KPS). AEs, including leukopenia, thrombocytopenia, diarrhea, nausea and vomiting, hypertension, neutropenia, albuminuria, oral mucositis, hand-foot syndrome, weakness, hemoglobin reduction, and myelosuppression, were also assessed.
statistical analysis
The analyses were performed using Review Manager 5.3 (Cochrane Collaboration, London, UK). P,0.05 was taken to indicate that the differences reached statistical significance. Heterogeneity among studies was assessed with the Cochran's Q test to determine the most suitable analysis model, and funnel plots were used to assess the publication biases of the involved studies.
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,50% or P.0.1 indicated that a study was homogenous. The OR was the principal measurement of the therapeutic effects, and the ORs are presented with the 95% CIs. Sensitivity analyses were conducted to evaluate the influences of the therapeutic regimens, apatinib dosages, sample sizes, and types of involved studies.
Results
search results
A total of 476 articles were identified in the initial search. After review of the titles and abstracts, 384 articles were excluded because they did not include clinical trials (n=207), 
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Apatinib combined with CT for gastric cancer were unrelated studies (n=56), or were duplications or repetitions (n=121). This process left 92 studies as potentially relevant. After detailed assessment of the full texts, case reports and reviews (n=16), and articles without a control group (n=17) or without apatinib and CT combined therapy (n=23) or with insufficient data (n=4) were excluded. Finally, 19 trials 19-37 involving 1,256 advanced GC patients were included in this meta-analysis (Figure 1 ).
Patient characteristics
After selection, all of the included trials were conducted in the People's Republic of China. In total, 625 advanced GC patients were treated with apatinib in combination with CT, and 631 patients were treated with CT alone. Detailed information about the involved trials and patients is presented in Tables 1 and 2 .
Quality assessment
The assessment of bias risk is presented in Figure 2 . Fourteen studies were determined to be low risk, and the remaining 5 studies were not true randomized controlled trials. None of the included trials provided clear descriptions of the performance and detection risks. The attrition risks of the involved trials were low; 3 trials were considered to have unclear risk owing to selective reporting.
Therapeutic efficacy assessments
As presented in Figures 3 and 4 , Figure S1 , and 
QOl assessment
QOL was evaluated in this analysis. The results revealed that the QOL of patients in the combined group was significantly better than that of the control group as indicated by the QIR and KPS, although the former did not reach significance ( 
aes assessment
The safety of apatinib targeted therapy was evaluated in this meta-analysis. As presented in Figure S2 and 
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Study or subgroup
Publication bias
The funnel plots drawn for the studies of the primary outcomes (CR, PR, SD, PD, ORR, DCR, and AEs) were approximately symmetrical, which indicated the generally controlled publication bias and reliability of our primary conclusions ( Figures 6 and S3 and S4 ).
sensitivity analysis
We conducted subgroup analyses to explore the sources of heterogeneity in the ORR and DCR with respect to therapeutic regimens, apatinib dosages, sample sizes, and types of involved studies. As presented in Table 5 , our analysis results revealed that no significant differences were found between the different therapeutic regimens, apatinib dosages, sample sizes, and types of studies.
Discussion
In recent years, with the development of tumor molecular biology and epigenetics, increasing numbers of targeted agents, such as gefitinib, erlotinib, apatinib, etc, have been used to improve treatment effects for patients with malignancies. [40] [41] [42] [43] As components of the important signaling pathway of cancer angiogenesis, VEGF and VEGFR are closely related to cancer invasiveness. Researchers have confirmed that the expressions of VEGF and VEGFR are associated with poor prognosis in GC. 44, 45 Upon binding to its receptors, the activated VEGF family promotes the proliferation of vascular cells for the development of new blood vessels in tumor tissues and then ensures oxygen and nutrient supplies and causes tumor growth and metastasis. 14, 46 Therefore, anti-VEGFR target drugs are considered promising prospects for the treatment of advanced GC.
The VEGFR family includes VEGFR-1, VEGFR-2, and VEGFR-3. 16 Among these receptors, VEGFR2 plays an essential role in VEGF-mediated tumor angiogenesis. 14, 17 When it associates with VEGF, the dimerization of VEGFR2 causes the autophosphorylation of intracellular tyrosine kinase domains, which leads to the activation of the PLC-γ-Raf kinase-MEK-MAP kinase pathway, which in turn enhances endothelial cell proliferation. 14, 15 Apatinib is a new inhibitor of VEGFR-2 tyrosine kinase that targets the intracellular ATP binding site of the receptor. 17 Several studies have reported that the addition of apatinib can be beneficial for patients with advanced GC. 42, 43 Although there are statistical analyses of published clinical trials, the exact therapeutic effects have not been systematically evaluated and demonstrated due to sample size variability among these trials. Additionally, the different applied protocols in the different clinical trials may have led to different therapeutic effects. In the present research, we performed an extensive online search followed by rigorous contrasting and combining data analyses in terms of categorization to provide a clear and systematical conclusion. Our meta-analysis revealed that apatinib targeted therapy combined with CT is associated with a favorable efficacy compared with CT alone. Compared with the patients who were treated with CT alone, the patients who were treated with combined therapy exhibited markedly increased CR, PR, ORR, and DCR (P,0.05). The patients' QOL was also evaluated in this analysis, and the QOL was significantly improved after combined therapy. These results indicated that apatinib targeted therapy increased the curative effect of CT by inhibiting tumor angiogenesis and thereby improving the patients' life qualities.
Safety is the top priority of clinical treatment, and it is also the key factor for the development of apatinib targeted therapy. Regarding AEs and severe toxicities, our analysis revealed that there were no significant differences in most of the AE indicators between the 2 groups. The group receiving CT plus apatinib targeted therapy had higher rates of hypertension, proteinuria, and hand-foot syndrome, which are usually controllable events and do not require permanent discontinuation of therapy.
Some factors may influence the therapeutic effects of apatinib targeted therapy. In our subgroup analysis, no differences were found between the different therapeutic regimens, apatinib dosages, sample sizes, and types of studies. However, currently published studies that have probed the influences of these factors on the curative effect of apatinib targeted therapy are still insufficient; thus, these issues should be further researched and explored. Furthermore, the determination of the optimal therapeutic strategy will be valuable for GC treatment. Recently, many novel treatment strategies, such as targeted therapy and immunotherapy, have been developed for the treatment of malignancies. Several Drug Design, Development and Therapy 2018:12 submit your manuscript | www.dovepress.com
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cheng et al studies have found that combined treatment with targeted therapy and immunotherapy for malignant tumors has better therapeutic effects than single therapy. 47, 48 Therefore, the combination of targeted therapy with an immunotherapy, such as chimeric antigen receptor-modified T cells, T-cell receptor-modified T cells, etc, 49, 50 may be the new direction for the future development of advanced GC treatment.
There are some limitations in our analysis. First, the number of GC patients included in this study is not sufficiently large, and the follow-up time was short. Apart from that, the different trials evaluated the treatment efficacy using different outcomes, so it was difficult to summarize the results on the same scale, which led to shrunken statistical sample sizes. Third, our data were partly extracted from published papers rather than original patient records, which mean that we were not able to avoid analytical bias based on the information presented in the articles. Due to the above limitations, future studies and generated data will be valuable to further verify the safety and efficacy of apatinib targeted therapy.
Conclusion
In summary, our study confirmed that apatinib targeted therapy combined with CT is an effective treatment for advanced GC patients. Apatinib targeted therapy markedly enhances the treatment efficacy of CT for advanced GC. However, this combined treatment could lead to greater rates of hypertension, albuminuria, and hand-foot syndrome. Therefore, the benefits and risks should be considered before treatment.
